Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Kerry A Rogers, Qiuhong Zhao, Seema A Bhat, John C. Byrd, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Gerard Lozanski, Margaret S. Lucas, Lindsey Rike, Shanmugapriya Thangavadivel, William E. Carson III, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2023-180308

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Counting Chromosome Abnormalities in Chronic Lymphocytic Leukemia: Comparison of Iscn 2020 and MDS International Working Group Guidelines for Establishing Karyotype Complexity

Cecelia Miller, Ying Huang, Adam S Kittai, Seema A Bhat, Kerry A Rogers, Michael R. Grever, Jennifer A. Woyach, Matthew R Avenarius

Blood (2023) 142 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2023-180807

Published: 2023

Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2023-180294

Published: 2023

Journal Articles

Two-inhibitor salvage therapy for hairy cell leukemia

Michael R. Grever

Blood (2023) 141 (9): 965–966.

https://doi.org/10.1182/blood.2022018319

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Kristin L Koenig, Prachi Jain, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Jennifer A. Woyach, Michael R. Grever, Uma Borate, Alice S. Mims, Daniel Jones, Cecelia Miller, James S. Blachly, Adam S Kittai

Blood (2022) 140 (Supplement 1): 4071–4073.

https://doi.org/10.1182/blood-2022-168274

Published: 2022

Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller

Blood (2022) 140 (Supplement 1): 7016–7017.

https://doi.org/10.1182/blood-2022-163753

Published: 2022

Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 4166–4168.

https://doi.org/10.1182/blood-2022-167314

Published: 2022

Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever

Blood (2022) 140 (Supplement 1): 6494–6495.

https://doi.org/10.1182/blood-2022-165795

Published: 2022

Journal Articles

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Andrew Stiff, Qiuhong Zhao, Nilesh Kapoor, Kerry A. Rogers, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Gerard Lozanski, Michael R. Grever, Seema A. Bhat

Blood (2022) 140 (Supplement 1): 6524–6525.

https://doi.org/10.1182/blood-2022-166619

Published: 2022

Journal Articles

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A. Bhat, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Narendranath Epperla, Zeinab El Boghdadly, Michael R. Grever, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 9361–9362.

https://doi.org/10.1182/blood-2022-156720

Published: 2022

Journal Articles

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach

Blood (2021) 138 (23): 2372–2382.

https://doi.org/10.1182/blood.2020010536

Published: 2021

Includes: Supplemental data

Journal Articles

Characterization of Cytotoxic Macrophages in a Pre-Clinical Model of Epstein-Barr Virus (EBV)-Driven Lymphoproliferative Disease

John Patton, Emily Smith, Zahary Smith, Andrew Stiff, A. Douglas Kinghorn, Yiping Yang, Michael R Grever, David M. Lucas, Robert Baiocchi

Blood (2021) 138 (Supplement 1): 3502.

https://doi.org/10.1182/blood-2021-154161

Published: 2021

Journal Articles

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Adam S Kittai, Ying Huang, Ashleigh Keiter, Kyle A Beckwith, Daniel Goldstein, Seema A Bhat, David A. Bond, John C. Byrd, Michael R Grever, Kerry A Rogers, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 3731.

https://doi.org/10.1182/blood-2021-144518

Published: 2021

Journal Articles

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Cecelia Miller, Ying Huang, Jonathan Hyak, Matthew R Avenarius, Amy S. Ruppert, John C. Byrd, Seema A Bhat, Michael R Grever, Adam S Kittai, Kerry Rogers, Nyla A. Heerema, Lynne V. Abruzzo, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2021-150722

Published: 2021

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Leylah Azali, PharmD, Lindsay Hazelden, PharmD, Tracy Wiczer, PharmD, Marilly Palettas, Rebekah Thomas, Connor Aossey, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Daniel Addison, MD, Seema A Bhat, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137800

Published: 2020

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

NARROW

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Counting Chromosome Abnormalities in Chronic Lymphocytic Leukemia: Comparison of Iscn 2020 and MDS International Working Group Guidelines for Establishing Karyotype Complexity

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Two-inhibitor salvage therapy for hairy cell leukemia

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Characterization of Cytotoxic Macrophages in a Pre-Clinical Model of Epstein-Barr Virus (EBV)-Driven Lymphoproliferative Disease

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only